NCT06144944
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 21 words
- Primary endpoints: details revised at 1 of 1 entry
- Study completion moved earlier from Dec 31, 2031 to Jan 31, 2031
- Secondary endpoints: details revised at 2 of 10 entries
- Minor Primary completion date changed from estimate of Jun 30, 2026 to Jul 18, 2026v7
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Eligibility criteria shortened, about 2 words
- Interventions: Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Drug), Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel… to Epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Drug), Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Drug)
- Study title shortened, about 4 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 1, 2024 to Jan 17, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Residual Cancer Burden 0/1 rate as assessed by independent central review
Timeframe: Within 4 weeks after surgery
Secondary (10)
Residual Cancer Burden 0/1 rate as assessed by local pathology review
Pathological complete response rate
Objective response rate
Breast conservation surgery rate
Health-related Quality of Life 1
Show 5 moreShow less
Health-related Quality of Life 2
5-year event-free survival
5-year overall survival
Safety (AEs+SAEs)
Biomarkers (Immune cell subpopulations quantities)
Arms and interventions
Neoadjuvant pyrotinib combined with chemotherapyExperimental
Neoadjuvant chemotherapyPlacebo comparator
Drugs: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Sites
1 site in 1 country
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China